New CGM Device for Type 2 Diabetes

19 Jul 2022
healthtechinsider.com
MySugarWatch has pushed the pedal on an awareness campaign for its continuous non-invasive glucose monitor called sugarBEAT. MySugarWatch is the UK licensee of Nemaura Medical, a company specializing in developing wearable diagnostic devices. The company aims to cater to the awareness needs of the people with pre-diabetes and diabetes. The campaign, featured in the DailyMail, is set to reach about 1.2 million people. MySugarWatch aims to eliminate skin-pricks test strips historically used by patients to monitor blood sugar level for Type-2 diabetes patients. Studies show that 3.6 million in the UK suffer from Type-2 Diabetes while a further 12.3 million people are at risk of developing the disorder. MySugarWatch adds to the list of continuous glucose monitoring devices. It monitors your blood sugar level every 5 minutes, providing consistent data. The data is then stored in a dedicated app, which maps the 168 glucose level readings taken during the day. This allows you to identify trends and monitor Time-in-Range right from your phone. The device does require calibration with a finger stick; a reading each morning before eating is recommended. Continuous Glucose Monitoring (CGM) was difficult to achieve so far due to difficulties in procedure including regular needle insertion. CGMs like MySugarWatch that measure interstitial fluid glucose levels do not require a needle prick and easily allows patients to make lifestyle changes based on trends in their blood sugar level. These strategic changes will greatly help patients and healthcare professionals to manage, prevent and even reverse Type-2 pre-diabetes. MySugarWatch, unfortunately, is not for Type-1 diabetes patients, or patients who receive injectable insulin or who are taking sulfonylurea medications (Glibenclamide, Gliclazide, Glimepiride, Glipizide, Tolbutamide). As a result, it’s not completely useful as an “artificial pancreas” component. The product does have CE Mark clearance, but not FDA clearance yet.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.